The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs.
D052242:Adiponectin / Q000097:blood; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000209:etiology; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D001523:Mental Disorders / Q000188:drug therapy; D024821:Metabolic Syndrome / Q000097:blood* / Q000209:etiology; D009765:Obesity / Q000097:blood / Q000139:chemically induced; D049629:Waist-Hip Ratio
C499918:ADIPOQ protein, human; D052242:Adiponectin; D000928:Antidepressive Agents; D015415:Biomarkers; D020738:Leptin; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human